• MTT for HUVEC Viability and Angiogenesis Studies

  2026-08-20

  Use MTT to quantify HUVEC metabolic activity while pairing it with tube formation, migration, and pathway readouts for a more complete angiogenesis workflow. This guide translates findings from a critical limb ischemia study into practical assay design, optimization, and troubleshooting decisions.

• FLAG tag Peptide: Assay Design for Clean Elution

  2026-08-19

  The FLAG tag Peptide and DYKDDDDK peptide support gentle affinity elution while preserving recombinant protein function. This guide connects tag-based workflow design with the mechanistic assay lessons of a landmark Sin3L/Rpd3L HDAC study.

• Cy5.5 NHS Ester for Biodistribution Assays

  2026-08-19

  Cy5.5 NHS ester enables covalent near-infrared labeling of amine-containing biomolecules for biodistribution and in vivo fluorescence imaging. This guide connects dye chemistry with a 2025 polysaccharide absorption study to clarify tracer design, controls, and interpretation.

• KN-62: CaMKII Control for Translational Biology

  2026-08-18

  KN-62 offers a focused way to interrogate CaMKII within calcium-dependent signaling, metabolism, secretion, and cell-cycle biology. This thought-leadership perspective connects its established research applications with recent findings on calcium-driven autophagy in glioblastoma while clearly separating validated evidence from forward-looking experimental strategy.

• Bergenin–PPARγ–PROX1 Axis in Psoriasis

  2026-08-18

  A 2026 Phytomedicine study identifies bergenin as a plant-derived PPARγ agonist that suppresses pathogenic γδT17 cells in psoriasis models. Its central mechanistic contribution is linking PPARγ activation to PROX1 ubiquitination at K248, reduced fatty acid oxidation, epigenetic repression of IL17A, and lower psoriatic inflammation.

• Deferoxamine Mesylate: Iron and Hypoxia Research

  2026-08-17

  Deferoxamine mesylate is an iron-chelating agent that converts bioavailable iron into ferrioxamine and supports controlled studies of oxidative stress, hypoxia signaling, and iron-dependent cell injury. Product specifications and recent lysosomal biology together define useful research applications while showing why direct evidence must be separated from mechanistic extrapolation.

• VE-822 ATR Inhibitor: Reliable Assay Workflows

  2026-08-17

  This scenario-driven guide explains how VE-822 (SKU B1383) can improve experimental planning for cell viability, proliferation, and radiation-sensitization studies. It connects ATR biology with practical stock preparation, 2D/3D assay design, data interpretation, and evidence-based product selection.

• Wnt-C59: Selective PORCN Inhibition

  2026-08-16

  Wnt-C59 is a potent PORCN inhibitor that blocks Wnt ligand secretion and downstream Wnt/β-catenin signaling. Product data support its use in Wnt mechanism studies, cholangiocarcinoma research, and Wnt-driven tumor models, while the cited osteogenesis study illustrates the contrasting effects of increasing Wnt10a secretion.

• Wnt-C59: PORCN Inhibitor Workflows

  2026-08-15

  Wnt-C59 provides a highly selective way to test whether Wnt ligand secretion drives pathway activity, tumor-cell survival, or exosome-mediated signaling. This workflow-focused guide connects PORCN inhibition with reporter assays, cholangiocarcinoma models, and mechanistic studies inspired by recent Wnt10a exosome research.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-08-14

  This ACS Applied Materials & Interfaces study identifies a Rab11a–Rab11FIP1 trafficking mechanism through which lithium increases exosomal Wnt10a secretion from bone mesenchymal stem cells (BMSCs). Lithium-conditioned exosomes enhanced osteogenic differentiation, and their incorporation into GelMA hydrogels improved bone repair, linking intracellular vesicle trafficking with an exosome-based regenerative strategy.

• Bergenin Targets γδT17 Cells in Psoriasis

  2026-08-14

  A 2026 Phytomedicine study identifies bergenin as a PPARγ-dependent inhibitor of pathogenic γδT17-cell activity in psoriasis. Its key mechanistic advance is linking PPARγ activation to K248-linked PROX1 ubiquitination, reduced fatty acid oxidation, and suppression of IL-17A transcription.

• Cy3 NHS Ester (Non-Sulfonated): Lab Guide

  2026-08-13

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent label for accessible amino groups on soluble proteins, peptides, and appropriately modified oligonucleotides or DNA. It is water-insoluble and requires an organic co-solvent, so it should be reserved for workflows compatible with DMSO or DMF rather than delicate samples that cannot tolerate co-solvent exposure.

• Cy5.5 NHS Ester for Hydrogel Tracking

  2026-08-13

  Cy5.5 NHS ester (non-sulfonated) converts amino-bearing proteins, carriers, and modified oligonucleotides into near-infrared reporters for tracking retention, uptake, and biodistribution. Applied to the bioadhesive hydrogel strategy described in the reference study, it helps separate depot localization from genuine miRNA delivery and therapeutic response.

• A-1331852: Mapping BCL-XL Apoptotic Dependency

  2026-08-12

  A-1331852 is a selective BCL-XL inhibitor for investigating mitochondrial apoptosis and cancer-cell dependency. This article connects its mechanism to glioblastoma apoptotic priming and shows how to design assays that distinguish target engagement from true cellular dependence.

• Chronic Cabozantinib Remodeling in RCC

  2026-08-12

  This 2026 study shows that acute and chronic Cabozantinib exposure produce distinct phosphoproteomic states in renal cell carcinoma, rather than a simple extension of the early drug response. Persistent suppression of MET activation-loop phosphorylation coexisted with chronic adhesion-, stress-, and MAPK/AP-1-associated remodeling and modest, context-dependent changes in cell motility.

8510 records 2/568 page Previous Next 12345 下5页 Last page